Sei qui:

Primo ordine in Italia del sistema Raypilot Hypocat

Micropos is proud to announce the first RayPilot® HypoCath™ system order from Italy.
The order has been submitted by the company’s Italian distributor ELSE Solutions srl. which since August 2017 is Micropos distributor.

– After the launch of the RayPilot® HypoCath™ we have seen an increased interest from the Italian market and we have several deep discussions with potential end customers from both public and private clinics says Massimo Agosti, CEO at ELSE Solutions.

Micropos launched the RayPilot HypoCath as a new member of the RayPilot family at Europe’s largest radiotherapy congress, ESTRO in Barcelona in mid-April 2018.

– We developed RayPilot® HypoCath™ in order to give radiotherapy clinics that does not have the resources to surgically insert the RayPilot® Transmitter the opportunity to benefit for high precision prostate treatments. With the HypoCath™, the surgical procedure is no longer needed and therefore a major barrier for the clinics has been eliminated. This in combination with the recent proof of clinical evidence for hypofractionated treatments which are the type of treatments that RayPilot® is designed for makes us see an exciting future for the company, says Micropos CEO, Tomas Gustafsson.

The uniqueness of HypoCath is that, unlike competing systems, it is intended to be applied directly to the clinic’s existing workflow in a routine manner (including MRI-based workflows) and without the need for surgical procedures. HypoCath is designed as a urinary catheter where the RayPilot technology is integrated to enable real-time prostate motion detection. Increased precision and safety are one of the prerequisites for reducing the risk of unwanted side effects and for reducing the number of treatments through so-called hypofractionation.

– With the launch of the HypoCath™, we experience an increased interest from the market and we are very pleased to announce our first RayPilot® HypoCath™ system sales to Italy shortly after the presentation of the product. This shows that our focused development work by HypoCath™ and our marketing efforts now can begin to generate sales continues Micropos’ CEO, Tomas Gustafsson.